Page last updated: 2024-11-06

lysergic acid diethylamide and Huntington Disease

lysergic acid diethylamide has been researched along with Huntington Disease in 1 studies

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schwarcz, R1
Bennett, JP1
Coyle, JT1

Other Studies

1 other study available for lysergic acid diethylamide and Huntington Disease

ArticleYear
Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease.
    Journal of neurochemistry, 1977, Volume: 28, Issue:4

    Topics: Animals; Caudate Nucleus; Disease Models, Animal; Humans; Huntington Disease; Lysergic Acid Diethyla

1977